Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertensio

Not Applicable

• Conditions: pulmonary hypertension

• Registration Number: JPRN-UMIN000027411
• Lead Sponsor: agoya University

Brief Summary

unpublishied

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-01
• Study Completion: 2021-03-31
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

Not provided

Exclusion Criteria

1,Diagnosis of malignant tumor] 2,Diagnosis of myeloproliferative disorder 3,Diagnosis of inflammatory diseases 4,Patients already using pulmonary vasodilator (prostaglandin I 2 preparation, endothelin receptor antagonist, phosphodiesterase 5 inhibitor, soluble guanylate cyclase stimulant)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1,All deaths (cardiovascular death / non-cardiovascular death) 2,Exacerbation of pulmonary hypertension 3,If one of the following treatments is required I) Parenteral administration of prostanoid preparations Ii) When it is judged that lung transplantation or atrial atrial septation surgery is necessary at clinician's discretion

Secondary Outcome Measures

Name	Time	Method
1,Circulatory dynamics index (hemodynamic index by right heart catheterization) 2, Subjective symptoms: questionnaire (SF-36) 3,Serum biomarker 4,Cardiac ultrasound examination 5,Respiratory function test 6,Weight loss and discontinuation of home oxygen therapy (HOT) 7,Hospitalization due to occurrence of adverse event other than hospitalization due to pulmonary hypertension (Hospitalization due to cancer/cerebral infarction/myocardial infarction/left heart failure etc.)